Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

about

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.Increased Infiltration of CD8(+) T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab.

P2860

Q26781522-B0F4DC56-8010-4A23-A8CF-17D43C4D4991 Q37701461-D9E98634-C9E6-450A-B8A7-C0570B5D3B38 Q42087596-0E8D87DE-481D-48F8-B061-28353EFFF9B3

P2860

Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

Item

http://www.wikidata.org/entity/Q41545176

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Cancer chemotherapy agents tar ...... potentiate antitumor immunity.

@en

type

Item

label

Cancer chemotherapy agents tar ...... potentiate antitumor immunity.

@en

prefLabel

Cancer chemotherapy agents tar ...... potentiate antitumor immunity.

@en

P1476

Cancer chemotherapy agents tar ...... potentiate antitumor immunity.

@en

P2093

Alfred Zippelius

http://www.w3.org/2001/XMLSchema#string

Kea Martin

http://www.w3.org/2001/XMLSchema#string

Philipp Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Tumor Immunotherapy Directed at PD-1

Immunogenic cell death in cancer therapy

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Tumor-altered dendritic cell function: implications for anti-tumor immunity.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Breakthrough of the year 2013. Cancer immunotherapy.

The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.

P304

e954460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/21624011.2014.954460

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael von Bergwelt-Baildon

Sebastian Theurich

P577

2014-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273956143

http://www.w3.org/2001/XMLSchema#string

P698

25610745

http://www.w3.org/2001/XMLSchema#string

P932

4292760

http://www.w3.org/2001/XMLSchema#string

Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

about

P2860

P2860

Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932